Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

Invesco LLC slashed its Amgen holdings by 20.2%, unloading 2,310 shares worth roughly $2.85 million. This sale brought ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Oppenheimer & Co. Inc. trimmed its stake in Amgen Inc. by 1.2% in Q1, selling 1,335 shares, bringing its holding to 109,833 ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

Amgen said Monday it's expanding development plans for its weight-loss drug, MariTide, to include cardiovascular conditions ...

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, prevalent gastrointestinal side effects are leading the company to use a slow | ...